We have located links that may give you full text access.
Preexisting Atrial Fibrillation Associated with Higher Mortality in Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: Analysis of the National Inpatient Sample.
BACKGROUND: The purpose of this study was to investigate the prevalence of preexisting atrial fibrillation (AF) in patients with MRSA-BSI during a three-year period and the impact of preexisting AF on MRSA-BSI outcomes.
METHODS: This was a retrospective analysis performed using the National Inpatient Sample (NIS) over a three-year period (2016, 2017, 2018) for patients with MRSA-BSI as a principal diagnosis with and without preexisting AF. The primary outcome was mortality with secondary outcomes of acute coronary syndrome, cardiac arrest, cardiogenic shock, endocarditis, respiratory failure, acute kidney injury, length of stay, hospital cost, and patient charge. A univariate and multivariable logistic regression analysis estimated clinical outcomes.
RESULTS: Preexisting AF in patients with MRSA-BSI significantly increased the primary outcome of the study, mortality (1.67% vs. 0.66%, p =0.030) with an adjusted odds ratio (AOR) of 1.98 (95% CI, 1.1-3.7). Secondary outcomes showed increased likelihood of cardiac arrest with MRSA-BSI and AF (0.48% vs. 0.2%, p =0.025) with an AOR 3.59 (CI 1.18-11.0), ACS (3.44% vs. 1.21%, p =0.008) with an AOR of 1.81 (CI 1.16-2.80), respiratory failure (8.92% vs. 4.02%, p =0.045) with an AOR 1.39 (CI 1.01-1.91), prolonged LOS (6.4 vs. 5.4 days, p =0.0001), increased hospital cost ($13,374 vs. $11,401, p =0.0001), and increased overall patient charge ($50,091 vs. $43,018, p =0.0001). Secondary outcomes that showed statistical significance included ACS (1,497 (3.44%) vs. 113 (1.21%), p =0.008) with an AOR of 1.81 (CI 1.16-2.80), cardiac arrest (209 (0.48%) vs. 19 (0.2%), p =0.025) with an AOR 3.59 (CI 1.18-11.0), and respiratory failure (3,881 (8.92%) vs. 374 (4.02%), p =0.045 with an AOR 1.39 (CI 1.01-1.91).
CONCLUSIONS: Preexisting AF is a significant risk factor for mortality in patients admitted for MRSA-BSI and increases risk for cardiac arrest, respiratory failure, and ACS. Considerations should focus on early treatment and source control, especially with AF given the mortality risk, increased hospitalization cost, and prolonged LOS.
METHODS: This was a retrospective analysis performed using the National Inpatient Sample (NIS) over a three-year period (2016, 2017, 2018) for patients with MRSA-BSI as a principal diagnosis with and without preexisting AF. The primary outcome was mortality with secondary outcomes of acute coronary syndrome, cardiac arrest, cardiogenic shock, endocarditis, respiratory failure, acute kidney injury, length of stay, hospital cost, and patient charge. A univariate and multivariable logistic regression analysis estimated clinical outcomes.
RESULTS: Preexisting AF in patients with MRSA-BSI significantly increased the primary outcome of the study, mortality (1.67% vs. 0.66%, p =0.030) with an adjusted odds ratio (AOR) of 1.98 (95% CI, 1.1-3.7). Secondary outcomes showed increased likelihood of cardiac arrest with MRSA-BSI and AF (0.48% vs. 0.2%, p =0.025) with an AOR 3.59 (CI 1.18-11.0), ACS (3.44% vs. 1.21%, p =0.008) with an AOR of 1.81 (CI 1.16-2.80), respiratory failure (8.92% vs. 4.02%, p =0.045) with an AOR 1.39 (CI 1.01-1.91), prolonged LOS (6.4 vs. 5.4 days, p =0.0001), increased hospital cost ($13,374 vs. $11,401, p =0.0001), and increased overall patient charge ($50,091 vs. $43,018, p =0.0001). Secondary outcomes that showed statistical significance included ACS (1,497 (3.44%) vs. 113 (1.21%), p =0.008) with an AOR of 1.81 (CI 1.16-2.80), cardiac arrest (209 (0.48%) vs. 19 (0.2%), p =0.025) with an AOR 3.59 (CI 1.18-11.0), and respiratory failure (3,881 (8.92%) vs. 374 (4.02%), p =0.045 with an AOR 1.39 (CI 1.01-1.91).
CONCLUSIONS: Preexisting AF is a significant risk factor for mortality in patients admitted for MRSA-BSI and increases risk for cardiac arrest, respiratory failure, and ACS. Considerations should focus on early treatment and source control, especially with AF given the mortality risk, increased hospitalization cost, and prolonged LOS.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app